UNICYCIVE THERAPEUTICS, INC. Research and Development Expense
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Research and Development Expense of $2.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $2.79M, a 59.31% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $1.61M, a 25.98% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $2.25M, a 57.45% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $2.96M, a 2.66% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for fiscal 2025 was $9.12M, a 54.43% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for fiscal 2024 was $20.01M, a 55.12% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for fiscal 2023 was $12.90M, a 3.75% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. research and development expense for fiscal 2022 was $12.44M, a 104.54% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-12 | $4.40M 10-Q · filed 2026-08-12 | $6.64M derived: sum of 3 quarters · filed 2026-08-12 | $9.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-12 | $3.86M derived: sum of 2 quarters · filed 2026-05-12 | $6.82M derived: sum of 3 quarters · filed 2026-05-12 | $8.57M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.21M derived: sum of 2 quarters · filed 2026-03-30 | $6.96M derived: sum of 3 quarters · filed 2026-08-12 | $9.12M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.96M 10-Q · filed 2025-11-12 | $4.71M derived: sum of 2 quarters · filed 2026-08-12 | $6.87M 10-Q · filed 2025-11-12 | $12.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.75M 10-Q · filed 2026-08-12 | $3.94M 10-Q · filed 2026-08-12 | $9.21M derived: sum of 3 quarters · filed 2026-08-12 | $12.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.17M 10-Q · filed 2026-05-12 | $7.46M derived: sum of 2 quarters · filed 2026-05-12 | $10.50M derived: sum of 3 quarters · filed 2026-05-12 | $15.37M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.33M derived: sum of 2 quarters · filed 2026-03-30 | $13.20M derived: sum of 3 quarters · filed 2026-03-30 | $20.01M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.04M 10-Q · filed 2025-11-12 | $7.91M derived: sum of 2 quarters · filed 2025-11-12 | $14.73M 10-Q · filed 2025-11-12 | $18.96M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.87M 10-Q · filed 2025-08-14 | $11.68M 10-Q · filed 2025-08-14 | $15.91M derived: sum of 3 quarters · filed 2025-08-14 | $19.29M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $6.81M 10-Q · filed 2025-05-14 | $11.05M derived: sum of 2 quarters · filed 2025-05-14 | $14.42M derived: sum of 3 quarters · filed 2025-05-14 | $16.68M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.61M derived: sum of 2 quarters · filed 2025-03-31 | $9.87M derived: sum of 3 quarters · filed 2025-03-31 | $12.90M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.37M 10-Q · filed 2024-11-13 | $5.64M derived: sum of 2 quarters · filed 2024-11-13 | $8.67M 10-Q · filed 2024-11-13 | $12.51M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.27M 10-Q · filed 2024-08-14 | $5.30M 10-Q · filed 2024-08-14 | $9.14M derived: sum of 3 quarters · filed 2024-08-14 | $13.94M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $3.03M 10-Q · filed 2024-05-13 | $6.87M derived: sum of 2 quarters · filed 2024-05-13 | $11.67M derived: sum of 3 quarters · filed 2024-05-13 | $13.53M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $8.64M derived: sum of 2 quarters · filed 2024-03-28 | $10.50M derived: sum of 3 quarters · filed 2024-03-28 | $12.44M 10-K · filed 2024-03-28 |
| 2022-09-30 | $4.80M 10-Q · filed 2023-11-14 | $6.66M derived: sum of 2 quarters · filed 2023-11-14 | $8.60M 10-Q · filed 2023-11-14 | $9.96M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.86M 10-Q · filed 2023-08-14 | $3.79M 10-Q · filed 2023-08-14 | $5.15M derived: sum of 3 quarters · filed 2023-08-14 | $8.93M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.93M 10-Q · filed 2023-05-16 | $3.29M derived: sum of 2 quarters · filed 2023-05-16 | $7.07M derived: sum of 3 quarters · filed 2023-05-16 | $7.56M derived: sum of 4 quarters · filed 2023-05-16 |
| 2021-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $5.14M derived: sum of 2 quarters · filed 2023-03-31 | $5.63M derived: sum of 3 quarters · filed 2023-03-31 | $6.08M 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.78M 10-Q · filed 2022-11-14 | $4.27M derived: sum of 2 quarters · filed 2022-11-14 | $4.72M 10-Q · filed 2022-11-14 | $5.10M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $493.00K 10-Q · filed 2022-08-15 | $942.00K 10-Q · filed 2022-08-15 | $1.32M derived: sum of 3 quarters · filed 2022-08-15 | $1.63M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $450.00K 10-Q · filed 2022-05-12 | $832.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.14M derived: sum of 3 quarters · filed 2022-05-12 | $1.32M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $686.00K derived: sum of 2 quarters · filed 2022-03-31 | $868.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.01M 10-K · filed 2022-03-31 |
| 2020-09-30 | $304.00K 10-Q · filed 2021-11-12 | $486.00K derived: sum of 2 quarters · filed 2021-11-12 | $633.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $182.00K 10-Q · filed 2021-08-16 | $329.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |